Goldman Sachs analyst Richard Law initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $30 price target The company’s lead asset, VK2735, is a dual GLP-1/GIP agonist being ...

Goldman Sachs assumed coverage of Johnson & Johnson with a Buy rating and $172 price target The firm says concerns around the Stelera loss of exclusivity are overdone. Consensus estimates are ...

March 06, 2025 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) (the “Company”) announced today that its board of directors authorized and declared a quarterly dividend of $0.05 ...

TWO Two Harbors Investment Corp.

Create a list of the investments you want to track.

Create a list of the investments you want to track.